A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).

Authors: Yoshihiro Miyata, Ryota Shibaki, Hiroaki Akamatsu, Mitsuo Osuga, Yasuhiro Koh, Kenta Murotani, Kazumi Nishino, Terufumi Kato, Kazushige Wakuda, Tetsuya Mitsudomi, Kenichi Yoshimura, Nobuyuki Yamamoto

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20004

Source: Full article

---

Abstract

e20004